IRD Company Profile and Key Details

Opus Genetics, Inc. (NASDAQ:IRD) closed at $5.18 USD, gaining $0.06 (1.17%) from the previous close of $5.12. The stock is currently mid-range between its 52-week high and low $0.90 and $5.81. With a market capitalization of about $369.86 million, Opus Genetics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.63). Key stats such as the average daily volume over the past year has been around 909.70 thousand shares, trading with heavier-than-usual volume. Headquartered in Durham, MI, Opus Genetics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO George Magrath, the company employs approximately 18 people and listed since January 19, 2015. Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.

IRD has shown sold momentum, gaining 10.24% over the past week and 20.86% over the past quarter, though year-to-date performance is up 12.44%. Short-term trend indicators are bearishly aligned (SMA20 13.28%, SMA50 39.51%, SMA200 106.75%). The stock’s 14-day RSI is 62.44 (firm momentum), while the ATR of 0.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -9.46% below its high and over 452.31% above its low. Average 10-day trading volume of 967.66 thousand shares is in line with the 3-month average of 901.84 thousand, indicating normal recent market interest.

Opus Genetics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.26. This means the shares are trading below this model’s fair value.

Opus Genetics, Inc. generated EPS of -$1.72 over the past year. Five-year average earnings growth is 24.32%. Wall Street analysts project EPS growth of 9.28% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $5.00. The high target offers 189.58% upside. The low target suggests -3.47% downside. The mean target is $9.25. This offers 78.57% upside. Opus Genetics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 10, 2026, missed forecasts by 27.27%. The prior quarter beat by 105.91%. Over the last six quarters, Apple has recorded several small beats. These include -3.33% in November 12, 2024.

Opus Genetics, Inc. has 59.91 million shares outstanding. The public float is 30.28 million shares, elevated short interest at 0.45% of float. This equals 255.25 thousand shares. The short ratio is 1.05 days. Institutional investors hold 43.96% of the float. Insiders own 14.47%. Foundation Fighting Blindness Retinal Degeneration Fund holds 5.49 million shares, Magrath George has 1.74 million shares and YERXA BENJAMIN R has 711.54 thousand shares. Over the past six months, insider transactions show net selling. They sold 4.07 million shares across 11 transactions.

Our AI price prediction model suggests that Opus Genetics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.51%, with price expected at $5.05 by May 26, 2026, within a range of $4.72 to $5.38 3-Month Outlook: Projected rise of 87.45%, reaching $9.71 by August 10, 2026, with a range of $9.66 to $9.79. 1-Year Outlook: Projected gain of 316.8%, with price at $21.59 by May 12, 2027, within a range of $21.56 to $21.63.

Opus Genetics, Inc. (NASDAQ:IRD) shares are up 12.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Opus Genetics, Inc. trading at a premium to the broader market with a P/E of -40.99. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $9.05, suggesting 74.71% upside. Our AI forecast model points to short-term weakness (-2.51% over two weeks), a medium-term rise (87.45% over three months), and a longer-term gain (316.8% over one year), with expected trading ranges indicating moderate volatility.

Opus Genetics, Inc. trades at a P/E ratio of -40.99, slightly below the S&P 500 average, with a price-to-sales ratio of 36.65 and a price-to-book ratio of -95.62 indicating negative book value, which may reflect financial stress. The P/FCF stands at -10.22, also below market averages.